Dale B. Evans

发表

Cardiovascular pharmacology of the cardiotonic, imazodan (Cl‐914)

R. McNish, H. R. Kaplan, R. Steffen, 1986 .

Chapter 10. Cardiotonic Agents for the Treatment of Heart Failure

J. Bristol, Dale B. Evans, D. B. Evans, 1981 .

Chapter 9 β-Adrenergic Receptor Blockers as Therapeutic Agents

F. Hauck, Dale B. Evans, T. FoxRita, 1979 .

Anti-arrhythmic action of nadolol, a β-adrenergic receptor blocking agent

R. Lee, R. Laffan, M. T. Peschka, 1976 .

Agents for the treatment of heart failure

D. B. Evans, J. Bristol, Dale B. Evans, 1983, Medicinal research reviews.

Differential Vasorelaxant Effects of Milrinone and Amrinone on Contractile Responses of Canine Coronary, Cerebral, and Renal Arteries

P. Silver, A. Harris, A. Alousi, 1989, Journal of cardiovascular pharmacology.

Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

D. B. Evans, S. D. Burrows, M. Quade, 1986, Biochemical pharmacology.

CARDIOTONIC AGENTS. 1. 4,5-DIHYDRO-6-(4-(1H-IMIDAZOL-1-YL)PHENYL)-3(2H)-PYRIDAZINONES: NOVEL POSITIVE INOTROPIC AGENTS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE

W. Moos, I. Sircar, J. Bristol, 1985 .

Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

D. B. Evans, R. Lee, R. Laffan, 1975, European journal of pharmacology.

Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.

R. Bentley, D. B. Evans, P. Silver, 1988, European journal of pharmacology.

Adenosine receptors mediating cardiac depression.

D. B. Evans, J. Bristol, J. A. Schenden, 1982, Life sciences.